TW200633705A - Treatment of macular degeneration with lonidamine - Google Patents

Treatment of macular degeneration with lonidamine

Info

Publication number
TW200633705A
TW200633705A TW094145759A TW94145759A TW200633705A TW 200633705 A TW200633705 A TW 200633705A TW 094145759 A TW094145759 A TW 094145759A TW 94145759 A TW94145759 A TW 94145759A TW 200633705 A TW200633705 A TW 200633705A
Authority
TW
Taiwan
Prior art keywords
lonidamine
macular degeneration
treatment
administering
treated
Prior art date
Application number
TW094145759A
Other languages
English (en)
Inventor
George Tidmarsh
Steve Ammons
Original Assignee
Threshold Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Threshold Pharmaceuticals Inc filed Critical Threshold Pharmaceuticals Inc
Publication of TW200633705A publication Critical patent/TW200633705A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW094145759A 2004-12-23 2005-12-22 Treatment of macular degeneration with lonidamine TW200633705A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63905504P 2004-12-23 2004-12-23

Publications (1)

Publication Number Publication Date
TW200633705A true TW200633705A (en) 2006-10-01

Family

ID=36615495

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094145759A TW200633705A (en) 2004-12-23 2005-12-22 Treatment of macular degeneration with lonidamine

Country Status (2)

Country Link
TW (1) TW200633705A (zh)
WO (1) WO2006071897A2 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008001811A1 (de) * 2008-05-15 2009-11-19 Beiersdorf Ag Kosmetische Zubereitungen zur Verminderung von Schweißgeruch mit ABCC-Modulatoren
KR102377008B1 (ko) * 2019-07-01 2022-03-21 서울대학교산학협력단 Mct 발현 또는 활성 억제제를 유효성분으로 포함하는 혈관신생 관련 안과 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2331620A1 (en) * 1998-05-11 1999-11-18 The Endowment For Research In Human Biology, Inc. Use of neomycin for treating angiogenesis-related diseases

Also Published As

Publication number Publication date
WO2006071897A3 (en) 2006-10-19
WO2006071897A2 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
ATE540690T1 (de) Insulinkombinationen
WO2007087468A3 (en) Adiponectin for treatment of various disorders
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
HK1120441A1 (en) Drugs for treatment of ovarian cancer
WO2008000513A3 (en) Peptide compounds for the treatment of hyperexcitability disorders and diseases associated with ion channel dysfunction
BRPI0510094A (pt) uso de flibanserina no tratamento pré-menstrual e outros distúrbios sexuais femininos
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
MY176938A (en) 3,5-disubstituted and 3,5,7-trisubstituted-3h-oxazolo and 3h-thiazolo[4,5-d] pyrimidin-2-one compounds and prodrugs thereof
WO2007098089A3 (en) Treatment of hyperproliferative diseases with methotrexate n-oxide and analogs
WO2007098091A3 (en) Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
HK1124546A1 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
HK1125040A1 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
PL1919466T3 (pl) Formulacje do leczenia nieprawidłowości lipoproteinowych obejmujące statynę i pochodną metylonikotynoamidu
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
WO2008090287A3 (fr) Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida
SE0400184D0 (sv) New therapeutical use
TW200724146A (en) Use of LGG in the manufacture of a medicament for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant
GB0416508D0 (en) Therapeutic agents
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2007056301A3 (en) Antibody therapy for treatment of diseases associated with gluten intolerance
TW200735886A (en) Prevention and treatment of ocular side effects with a cyclosporin
NZ595364A (en) TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC beta-CELL DYSFUNCTION
EA200801238A1 (ru) Аналог диазонамида а